Bristlecone Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bristlecone Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,117	Closed	-$223K	–	292
2024 Q1	$223K	Sell	4,117 -270	-6%	-$13.8K	0.02%	265
2023 Q4	$225K	Sell	4,387 -490	-10%	-$25.7K	0.02%	253
2023 Q3	$283K	Buy	4,877 +8	+0.2%	+$490	0.03%	216
2023 Q2	$311K	Buy	4,869 +287	+6%	+$19.2K	0.03%	215
2023 Q1	$318K	Buy	4,582 +506	+12%	+$35.7K	0.03%	214
2022 Q4	$293K	Buy	4,076 +6	+0.1%	+$452	0.04%	210
2022 Q3	$289K	Sell	4,070 -53	-1%	-$3.85K	0.04%	201
2022 Q2	$317K	Buy	4,123 +6	+0.1%	+$457	0.04%	198
2022 Q1	$301K	Sell	4,117 -220	-5%	-$14.8K	0.04%	197
2021 Q4	$270K	Buy	4,337 +7	+0.2%	+$411	0.03%	198
2021 Q3	$256K	Buy	4,330 +800	+23%	+$52.7K	0.03%	192
2021 Q2	$236K	Buy	3,530 +45	+1%	+$2.93K	0.03%	198
2021 Q1	$220K	Buy	+3,485	New	+$217K	0.03%	198
2020 Q1	–	Sell	-9,141	Closed	-$587K	–	158
2019 Q4	$587K	Buy	+9,141	New	+$524K	0.12%	126
2019 Q3	–	Sell	-5,424	Closed	-$246K	–	145
2019 Q2	$246K	Buy	+5,424	New	+$253K	0.06%	162
2016 Q2	–	Sell	-3,990	Closed	-$255K	–	140
2016 Q1	$255K	Buy	+3,990	New	+$252K	0.1%	144

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bristlecone Advisors's BMY Position: Q2 2024 in Review

Bristlecone Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 4,117 shares — an estimated $223K sold.

Bristlecone Advisors first reported a position in BMY in Q1 2016 and held it in 16 quarters. The position peaked at $587K in Q4 2019. 2,152 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Bristlecone Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
Bristlecone Advisors sold 4,117 Bristol-Myers Squibb shares in Q2 2024, an estimated $223K.
Bristlecone Advisors first reported a position in Bristol-Myers Squibb in Q1 2016 and held it in 16 quarters.
Bristlecone Advisors's Bristol-Myers Squibb position peaked at $587K in Q4 2019.
2,152 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Bristlecone Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.